Scholarlink

Background <p>Adjuvant therapy after neoadjuvant treatment and R0 esophagectomy for esophageal squamous cell carcinoma (ESCC) remains controversial, and benefit may vary by post-neoadjuvant pathology. We evaluated heterogeneity of adjuvant benefit across prespecified pathologic strata and quantified absolute survival gains.</p> Methods <p>In this two-center retrospective cohort (January 2018–May 2023), patients with ESCC who underwent neoadjuvant therapy followed by R0 resection were classified as pCR (ypT0N0), ypT+N0, or ypT0–4N+. The exposure was early postoperative adjuvant therapy initiated within 8 weeks after surgery. To reduce immortal-time bias, we used an 8-week landmark design with follow-up from the landmark. Confounding was addressed using stabilized inverse probability of treatment weighting (sIPTW) based on preoperative covariates, center, and surgical approach. Outcomes were overall survival (OS) and disease-free survival (DFS) using weighted Cox models with robust standard errors; absolute differences in survival probability (ΔS) were derived from weighted Kaplan–Meier curves.</p> Results <p>Among 781 patients (pCR 142, ypT+N0 317, ypT0–4N+ 322), survival for pCR and ypT+N0 largely overlapped, whereas ypT0–4N+ had consistently worse outcomes. In the overall cohort, adjuvant therapy was not associated with improved OS (HR 0.99, 95% CI 0.75–1.31; <i>P</i> = 0.946) or DFS (HR 1.15, 95% CI 0.89–1.48; <i>P</i> = 0.283). Benefit was concentrated in ypT0–4N+ (OS HR 0.48, 95% CI 0.33–0.72; <i>P</i> &lt; 0.001; DFS HR 0.64, 95% CI 0.46–0.90; <i>P</i> = 0.011), with ΔS +13.2 percentage points for DFS at 1 year and +21.0 percentage points for OS at 3 years. No clear benefit was observed in pCR or ypT+N0.</p> Conclusions <p>After neoadjuvant therapy and R0 resection for ESCC, post-neoadjuvant nodal status strongly stratified prognosis, with similar survival for pCR and ypT+N0. Adjuvant benefit is heterogeneous and concentrated in ypN-positive disease, supporting a pathology-informed, risk-adapted postoperative strategy targeting ypT0–4N+.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Heterogeneity of adjuvant therapy effectiveness across post-neoadjuvant pathologic strata in esophageal squamous cell carcinoma: a retrospective cohort study

  • 期刊论文

  • 发表日期：

    2026年6月22日

查看全文
  • Qiuchen Ge,
  • Xuanzhi Feng,
  • Chenglong Guo,
  • Tao Lu,
  • Jianhong Lian,
  • Jindong Li

摘要

Background

Adjuvant therapy after neoadjuvant treatment and R0 esophagectomy for esophageal squamous cell carcinoma (ESCC) remains controversial, and benefit may vary by post-neoadjuvant pathology. We evaluated heterogeneity of adjuvant benefit across prespecified pathologic strata and quantified absolute survival gains.

Methods

In this two-center retrospective cohort (January 2018–May 2023), patients with ESCC who underwent neoadjuvant therapy followed by R0 resection were classified as pCR (ypT0N0), ypT+N0, or ypT0–4N+. The exposure was early postoperative adjuvant therapy initiated within 8 weeks after surgery. To reduce immortal-time bias, we used an 8-week landmark design with follow-up from the landmark. Confounding was addressed using stabilized inverse probability of treatment weighting (sIPTW) based on preoperative covariates, center, and surgical approach. Outcomes were overall survival (OS) and disease-free survival (DFS) using weighted Cox models with robust standard errors; absolute differences in survival probability (ΔS) were derived from weighted Kaplan–Meier curves.

Results

Among 781 patients (pCR 142, ypT+N0 317, ypT0–4N+ 322), survival for pCR and ypT+N0 largely overlapped, whereas ypT0–4N+ had consistently worse outcomes. In the overall cohort, adjuvant therapy was not associated with improved OS (HR 0.99, 95% CI 0.75–1.31; P = 0.946) or DFS (HR 1.15, 95% CI 0.89–1.48; P = 0.283). Benefit was concentrated in ypT0–4N+ (OS HR 0.48, 95% CI 0.33–0.72; P < 0.001; DFS HR 0.64, 95% CI 0.46–0.90; P = 0.011), with ΔS +13.2 percentage points for DFS at 1 year and +21.0 percentage points for OS at 3 years. No clear benefit was observed in pCR or ypT+N0.

Conclusions

After neoadjuvant therapy and R0 resection for ESCC, post-neoadjuvant nodal status strongly stratified prognosis, with similar survival for pCR and ypT+N0. Adjuvant benefit is heterogeneous and concentrated in ypN-positive disease, supporting a pathology-informed, risk-adapted postoperative strategy targeting ypT0–4N+.